Table 2.
Prediction of therapy response in NSCLC by biomarkers.
| NSCLC | Response | N | Median | IQR | Range | p-Value |
|---|---|---|---|---|---|---|
| Pretherapeutic | ||||||
| HMGB1 | R NR |
41 38 |
2.84 2.84 |
3.9 3.6 |
0.3–13.4 0.3–13.2 |
0.641 |
| CEA | R NR |
35 34 |
5.10 5.85 |
9.6 26.2 |
1.7–2299 1.6–775 |
0.371 |
| CYFRA 21-1 | R NR |
35 34 |
4.40 6.65 |
8.2 10.0 |
0.0–67.0 0.3–72.0 |
0.453 |
| Cycle 2 | ||||||
| HMGB1 | R NR |
40 38 |
2.12 3.84 |
4.0 4.1 |
0.3–14.2 0.3–38.8 |
0.009 |
| CEA | R NR |
32 32 |
5.55 5.75 |
10.3 21.7 |
1.6–279 1.6–647 |
0.663 |
| CYFRA 21-1 | R NR |
33 32 |
2.30 6.25 |
4.0 10.2 |
0.3–51.6 1.0–54.0 |
0.006 |
| Cycle 3 | ||||||
| HMGB1 | R NR |
40 34 |
1.25 4.35 |
2.9 3.4 |
0.3–12.0 0.3–36.7 |
<0.001 |
| CEA | R NR |
39 24 |
5.30 6.90 |
9.9 15.7 |
1.4–2400 2.7–393 |
0.188 |
| CYFRA 21-1 | R NR |
38 26 |
2.30 8.60 |
3.5 13.3 |
0.5–92.7 1.1–68.1 |
<0.001 |
| Changes Cycles 1–2 (%) | ||||||
| HMGB1 | R NR |
41 38 |
62.8 106 |
87.8 119 |
0.0–1764 9.4–2446 |
0.008 |
| CEA | R NR |
35 34 |
85.7 97.4 |
57.4 44.6 |
0.0–290 0.0–437 |
0.086 |
| CYFRA 21-1 | R NR |
34 34 |
61.2 97.9 |
59.0 120 |
0.0–305 0.0–500 |
0.001 |
| Changes Cycles 1–3 (%) | ||||||
| HMGB1 | R NR |
41 38 |
50.2 84.3 |
103 151 |
0.0–1096 0.0–2317 |
0.058 |
| CEA | R NR |
35 34 |
92.3 89.2 |
71.1 138 |
0.0–340 0.0–702 |
0.621 |
| CYFRA 21-1 | R NR |
34 34 |
53.8 79.0 |
63.1 178 |
0.0–461 0.0–1833 |
0.213 |
Median concentrations, ranges and comparison between responders (R = remission and no change; upper rows) and non-responders (NR = progression; lower rows) of investigated biomarkers in NSCLC patients. Concentrations are given in ng/mL. IQR: interquartile range, HMGB1: high mobility group box 1 protein, CEA: carcinoembryonic antigen, CYFRA 21-1: cytokeratin 19-fragments. p-values in bold indicate statistically significant results, p-values in italics indicate statistical trends (p < 0.10).